Eli Lilly in talks to acquire Scorpion Therapeutics, FT says
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
The mergers and acquisitions market has already seen a flurry of deals at the start of 2025 across sectors. Here's a look at ...
Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. | For nearly a decade, Eli Lilly has been ...
Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...
In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...
The Biotech Ecosystem Venture Fund will combine the sourcing capabilities of venture capital firm Andreessen Horowitz (a16z) ...
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback